supporting global immunization – a humanitarian interest and a self interest pediatric grand...

1

Supporting Global Immunization – a Humanitarian Interest and a Self Interest

Pediatric Grand RoundsApril 4, 2012

Walter A. Orenstein MD, DSc (Hon)

2

Op-Ed from Steven Weinreb, an internist certified in oncology and hematology

• “I have chronic lymphocytic leukemia. Three months ago, I underwent an allogeneic stem-cell transplant ….” For the next seven months or so … I have a newborn’s immunity; I am prey to illnesses like chickenpox, the measles, and the flu.”

• “The truth is, we should not get vaccinated for ourselves alone; we should do it for one another.”

Source: New York Times, December 27, 2011

3

US National Vaccine Plan 2010• In the era of global pandemics and mass travel, the public

health of U.S. citizens is closely related to diseases occurring in other countries. Even though many VPDs such as polio, measles, and rubella have been eliminated in this country, the U.S. remains vulnerable to importations as long as these diseases continue to persist elsewhere. Support for overseas (pre-departure) vaccination of mobile populations, including refugees and immigrants migrating to the U.S., will reduce the likelihood of importation. Support for developing and introducing new vaccines to address diseases in other countries and assisting with strengthening and enhancing capacity of their immunization programs contributes toward providing an “umbrella of protection” for the U.S. and fulfilling the U.S. government’s broader commitment to global public health. http://www.hhs.gov/nvpo/vacc_plan/

4

Topics to be covered

• Basic background on herd immunity• Disease eradication as the ultimate goal (smallpox,

polio, measles)• Global burden of vaccine-preventable diseases• Measles as an “indicator disease” for problems• Global Immunization Structure• What pediatricians can do• Not covered – new vaccines and new technologies

that would help

5

Community Immunity - #1

Sustainedtransmission

Transmittingcase

Susceptible Transmittingcase

Susceptible

Transmittingcase

Immune

Transmissionterminated

6

Community Immunity - #2

Transmitting case

ImmuneImmuneImmuneImmune

Susceptible(IndirectlyProtected)

ImmuneSusceptible(IndirectlyProtected)

Immune

7

Source: Fine PEM, et al. Community Immunity in Plotkin SA, Orenstein WA, Offit PA, Vaccines 5th edition, Elsevier, 2008, pp 1573-1592

8Smallpox

10

Benefits of Smallpox Eradication to the US

• Sencer and Axnick documented in the United States during 1968:

• 14.2 million persons were vaccinated of whom 5.6 million were primary vaccinations and 8.6 million were revaccinations.

• Because of vaccine complications, 238 required hospitalization

• 9 died, and 4 were permanently disabled. • The total costs to the country, including the costs of

quarantine services, were estimated to be US$150 million.

Source: Henderson DA et al. Smallpox and Vaccinia in Vaccines 5th edition, 2008

11

Global U5 Mortality: Role of Vaccine Preventable Diseases (2008 data)

8.8 million under five deaths17% (1.5 million) from vaccine preventable diseases

Source: Black RE at all, Global, regional, and national causes of child mortality in 2008: a systematic analysis, Lancet. 2010 Jun 5;375(9730):1969-87. Epub 2010 May 11.* WHO/IVB estimates

Provided by Thomas Cherian via email 3/7/12

12

1.5 million Vaccine preventable deaths, children under age of 5, 2008

• Pneumococcal diseases* 476 000• Rotavirus* 453 000• Hib* 199 000• Pertussis 195 000

• Measles 118 000• Tetanus 63 000



13

1.5 million deaths among children from vaccine preventable disease by WHO regions, 2008



14

Measles

Selected Complications:

PneumoniaDiarrheaOtitis MediaEncephalitisSSPEKeratitisDeath

15

Measles Elimination, the Americas, 1980-2011*.

Source: Country reports to PAHO/WHO.*Data until EW 35/2011; coverage data not available for 2010.1 Ibdem Acharya et. al.

0

50,000

100,000

150,000

200,000

250,000

300,000

80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 110

20

40

60

80

100

Cases Coverage

Follow-up campaigns

Catch-up campaigns

Routine vaccination coverage (%)

Confi

rmed

cas

es

Interruption of endemic transmission

A total of 3.2 million measles cases and 16,000 deaths would have occurred between 2000-2020 if

PAHO strategies were not implemented. This resulted in a savings of US$ 208 million in

treatment costs.1Provided by Anne Schuchat, Presentation to NVAC 2/8/12

Measles, United States, 1996-Present

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

0

100

200

300

400

500

600

No

of C

ases

16Provided by Anne Schuchat, Presentation to NVAC 2/8/12

Measles, United States, 2011Geographic Distribution of Cases (n=222)

17

= 1 case

Provided by Anne Schuchat, Presentation to NVAC 2/8/12

Measles, United States, 2011Source of Importations, n=72

WHO RegionTotal no. of cases Countries

Genotype identified

African 4 Ethiopia (1), Kenya (2), Nigeria (1) B3 (4)

Eastern Mediterranean

3 Jordan (1), Pakistan (2) D4 (1)

European 33 Bulgaria (1), France (13), Italy (4), Poland (1), Romania (1), Spain (1), United Kingdom (5), France/Germany/Italy/Spain*(1), France/Germany/Spain* (1), France/Italy* (1), France/Spain/United Kingdom* (1), France/United Kingdom*(1), Hungary/Romania* (2)

D4 (16), G3 (1)

Americas 2 Canada (1), Dominican Republic†(1) D4 (1)

South-East Asia 19 Bangladesh (1), India (16), Indonesia (2) D8 (5), D4 (1)

Western Pacific 11 China (2), Malaysia (2), Philippines (6), Malaysia/Philippines/Singapore/Vietnam*(1)

H1 (1), D9 (6)

*Patient visited more than 1 country during the incubation period† Likely acquired disease from French tourist

18

72% of importations were among U.S. residents traveling abroadProvided by Anne Schuchat, Presentation to NVAC 2/8/12

19

2009 Imported Measles, U.S., as of 12/31/2009

D4

H1

71 cases 21 importations 12 imported virus cases

B3

CS2

0631

1-A

3

D4

D8

D8


Measles Outbreaks*United States, 2011

• 112/222 (50%) annual cases were outbreak-associated

• 17 total outbreaks• Median outbreak size was 6 (range: 3 – 21)• 44% of outbreak-associated cases were

unvaccinated philosophical belief exemptors

20*Outbreak = 3 Provided by Anne Schuchat, Presentation to NVAC 2/8/12or more epidemiologically linked cases

21

Impact of Selected Measles Importations Into the US in 2011 I

• Minnesota – 22 cases started by an unvaccinated child of Somali heritage, infected in Kenya, returned to the US and attended drop in child care

• Measles developed in 3 contacts at the center (including the first case, the infant living at the homeless shelter)

• Subsequent cases occurred in 2 homeless shelters, 2 health care facilities,2 households, and 1 other child care center. Fourteen children were hospitalized

From Hampton T, JAMA 2011;306:2440-2442

22

Impact of Selected Measles Importations Into the US in 2011 II

• Indiana – 14 cases started by a 24 year old unvaccinated US resident exposed in Indonesia, hospitalized with diagnosis of “Dengue Fever”

• Of the additional patients who were infected,10 exposed others in health care facilities.

• An investigation identified more than 780 persons who came in contact with infected individuals, including exposures in a church, factory, and school bus.


23

Impact of Selected Measles Importations Into the US in 2011 III

• Measles Salt Lake County, Utah - 9 cases traced back to an unvaccinated high school student who traveled to Europe

• Public health authorities investigated 49 confirmed or suspected cases, quarantined 184 individuals, and notified approximately 12 000 contacts.

• The Utah Department of Health, Salt Lake Valley Health Department, and Primary Children’s Medical Center estimated that the direct cost of health department and PCMC physician and staff time was $250 000 and the cost of vaccines, immunoglobulin, and blood work was approximately$41 700.

• Direct costs for controlling this outbreak conservatively totaled nearly $300 000.


Keys to Maintaining Measles Elimination in the U.S.

• High 2-dose MMR vaccination coverage• High quality surveillance system• Rapid identification of and response to measles cases• Measles is reportable within 24 hours per Council of

State and Territorial Epidemiologists guidelines• Aggressive outbreak control measures• Access to reliable laboratory testing capabilities• Genotyping can give clues to source in some instances• Information sharing tools (Epi-X, HAN)

24

Thinking beyond our borders


25

Vaccination of U.S.-Bound Refugees• 70,000 refugees resettled (70 nationalities from 100

countries) to 49 states annually• Refugees not legally required to get vaccinations before

U.S. resettlement– ~ 1/3 of refugees arrive in U.S. with no documented vaccinations

• > 40 VPD outbreaks in last 5 years– 1 recent imported measles case in Burmese refugee from Malaysia led to

8 cases in U.S., costly state/local PH response, and delayed resettlement of refugees

• Missed opportunity to vaccinate refugees between required overseas health assessment & arrival in U.S. (4-6 months)


26

Major causes of mortality among children <5 years 1990 vs. 2008

1990: 12.1 mil 2008: 8.8 mil

Measles accounts for ~23% of overall decrease in child mortality

Source: M. van den Ent et al, J Infect Dis Suppl, July 2011, pp S18-S23

Provided by Peter Strebel, via email 3/8/12

#1: India

RAJASTHAN

ORISSA

GUJARAT

MAHARASHTRA

MADHYA PRADESH

BIHAR

KARNATAKA

UTTAR PRADESH

ANDHRA PRADESH

JAMMU & KASHMIR

ASSAM

TAMIL NADU

CHHATTISGARH

PUNJAB

JHARKHAND

WEST BENGAL

ARUNACHAL PR.

HARYANA

KERALA

UTTARAKHAND

HIMACHAL PRADESH

MANIPUR

MIZORAM

MEGHALAYANAGALAND

TRIPURA

SIKKIM

GOA

A&N ISLANDS

D&N HAVELI

PONDICHERRY

LAK SHADWEEP

DELHI

CHANDIGAR H

DAMAN & DIU

Phase 2 (157 districts)

Phase 1 (45 districts covered)

Remaining (159 districts)

Source: Based on target population available with GoI

Target pop

(millions)

Vaccinated (millions)

Coverage

Phase-1 13.8 12.1 88%

Phase-2 42.9 28.6 67%*

Phase-3 72.7 Planned --

Total 129.4 40.7* --

* Phase-2 campaigns ongoing; data as on 23 Jan 2012.

17 states with MCV1 coverage ≥80% introduced a routine second dose by August 2011.

14 states with MCV1 <80% are implementing measles SIAs

Provided by Peter Strebel, via email 3/8/12

#2: Resurgence in Africa

• 4-fold increase since 2008• Large outbreaks in Burkina

Faso (2009), S. Africa (2010), and DRC (2011)

• Outbreaks in drought affected Horn of Africa – High case-fatality

0

100,000

200,000

300,000

400,000

500,000

600,000

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010‡

Year

No.

of c

ases

(in

thou

sand

s)

0

10

20

30

40

50

60

70

80

90

100

MCV1 coverage (%

)

Number of cases

WHO/UNICEF estimates

Administrative coverage

Weekly Epidemiological Record(2011) 86:129-136Source: Wkly Epid Rec, APRIL 2011, 86, 129–135 Provided by Peter Strebel via email 3/8/12

#3: Weak Immunization Systems

• 1st dose:– 67 Countries have MCV1

coverage <90%

• 2nd dose (routine):– 54 countries do not have

routine 2nd dose

• Campaigns:– Variable quality– Delayed

Measles 1st dose coverage among infants, 2010

80-89% (24 countries or 12 %)

50-79% (41 countries or 21%)

>=90% (126 countries or 66%)

<50% (2 countries or 1%)

Provided by Peter Strebel via email 3/8/12

1159

36 38 44

94

Measles Initiative Annual Donations 2001-2012 and Financial Resource Requirements, Projections, Funding Gap 2012-2015*

* Excludes all country contributions and direct social mobilization funding from partners30

Provided by Peter Strebel via email 3/8/12

31

Fatal Respiratory Diphtheria in a U.S. Traveler to Haiti --- Pennsylvania, 2003

Source: MMWR, January 9, 2004 / 52(53);1285-1286

In October 2003, the Pennsylvania Dept of Health and CDC were notified of a suspected case of respiratory diphtheria in a previously healthy Pennsylvania man aged 63 years who reported that he had never been vaccinated against diphtheria. He and seven other men from NY, PA, and W. VA. had returned from a week-long trip to rural Haiti, where they helped build a church.

32

Polio – a paralysing disease for life

33

Milestones on the way to Polio Eradication

Year Timeline

1985 Pan American Health Organization launches initiative to eradicate polio in the Americas by 1990

1988 World Health Assembly passes a resolution to eradicate polio by the year 2000

1994 Americas certified as polio-free. Last case indigenous case 1991

1999 Last outbreak of wild poliovirus type 2, Aligarh, India

2000 Western Pacific region certified polio free

2002 Europe certified polio free

2012 India without wild viruses detected for 1 year – Last case with onset 13 Jan 2011

34

1988

350,000 cases

125 endemic countries

World Health Assembly voted to eradicate polio

2011

650 cases reported (as of 20 March 2012)

4 endemic countries

3 countries with re-established transmission (sustained > 12 mos)

9 additional countries with transmission

Polio Cases

Selected Challenges Political commitment Management of human resources and accountability Inaccessible areas in endemic countries Continued quality SIAs with monitoring Area-specific gaps in surveillance quality Continuing outbreaks Funding

Source: Modified from Martin R, WHO, Polio, It’s everyone’s problem, NVAC February 8

36Source: Martin R, WHO, Polio, It’s everyone’s problem, NVAC February 8

37

Selected Key Organizations Involved in Global Immunization

• WHO• UNICEF• GAVI Alliance• Bill & Melinda Gates Foundation• US Organizations

– CDC– USAID– FDA– NIH

• Polio Eradication – Rotary International

38

WHO Mandate: Immunization Vaccines & Biologicals

• Housing scientific expertise and disseminating global immunization intelligence

• Convening the world's leading expertise in Immunization, Vaccines and Biologicals

• Facilitating technical cooperation with member states*, technical institutions, academia and public/private partnerships

• Coordinating technical assistance to member states• *194 Member States across Six Regional Offices

Source: McKinney S, USAID, Immunization: Global Architecture, NVAC February 8

39

UNICEF: Immunization Program Division

• UNICEF supports a wide array of activities at country, regional and global levels

• UNICEF works in support of governments and in collaboration with partners (e.g. GAVI)

• Focus on:– Demand creation and social mobilisation– Supply, logistics and cold chain systems– Reaching the Unreached (reduce inequities by focusing on

immunizing the “Fifth Child”)


Bill and Melinda Gates Foundation (BMGF)

• Investing billions in Global Health• Vaccines & Immunization – a focus of their global

health strategy• Discovery• Development• Delivery• Advocacy

• Multi pronged approach and a very engaged partner in many areas of vaccine development and immunization

• Positioned to take risks and do so gladly


41

USAID’s role

• USAID’s vaccines and immunization programs serve two functions:

– Donor agency – provide funds to areas that help to achieve our mission of reducing child mortality through immunization, (global, regional, country levels)

– Policy development - engage in policy dialogue and development (global and country level), and

– Technical support – engage in technical dialogue and development and to provide technical support (global and country level).


42

GAVI: Four strategic goalsStrategic plan 2011-2015

Accelerate the uptake of underused and new

vaccines

Contribute to strengthening the

capacity of integrated health systems to

deliver immunisation

Improve the sustainability of

national financing for immunisation and

increase predictability of global financing

Shape vaccine markets to provide appropriate vaccines at sustainable

prices


43

New vaccines and tiered pricing

Source: UNICEF Supply Division; CDC

44

GAVI: Children immunised with pneumococcal and rotavirus vaccines

Source: WHO-UNICEF coverage estimates for 1980-2010, as of July 2011. Coverage projections for 2011-2012, as of September 2011. World Population Prospects, the 2010 revision. New York, United Nations, 2010 (surviving infants).

45

Goal 5 of the National Vaccine Plan 2010

• Increase global prevention of death and disease through safe and effective vaccination

• Lists 6 objectives and strategies for achieving the goal

http://www.hhs.gov/nvpo/vacc_plan/

46

What Can Pediatricians Do? I

• Assure their patients are fully immunized for vaccines currently recommended in the US

• Assure their patients who are traveling receive all recommended vaccines for international travel (wwwnc.cdc.gov/travel/page/vaccinations.htm)

• Particularly important for measles for young infants – can vaccinate as young as 6 months (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6013a1.htm?s_cid=mm6013a1_w)

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6013a1.htm?s_cid=mm6013a1_w

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6013a1.htm?s_cid=mm6013a1_w

47

What Can Pediatricians Do? II

• Help make polio eradication a reality by working with local Rotary Clubs in their area

• Help in advocating with government officials about the importance of US government financial support and technical assistance for global immunization

• Volunteer for UNICEF– http://www.unv.org/how-to-volunteer/what-it-means-to-be-a-un-v

olunteer.html– http://www.unv.org/about-us/faqs.html#5

• A resource available from the American Academy of Pediatrics can be found at: (www2.aap.org/immunization/about/globalpartnerships.html)

http://www.unv.org/how-to-volunteer/what-it-means-to-be-a-un-volunteer.html

http://www.unv.org/how-to-volunteer/what-it-means-to-be-a-un-volunteer.html

http://www.unv.org/about-us/faqs.html

48

Acknowledgments

• Anne Schuchat and Rebecca Martin – CDC• Thomas Cherian, Peter Strebel, Marta Gacic-

Dobo, and Jean-Marie Okwo-Bele – WHO• Susan McKinney – USAID• Edward Hoekstra - UNICEF• Dianne Miller and Katy Seib - Emory

supporting global immunization – a humanitarian interest and a self interest pediatric grand...

Documents

dsc hon slide

preventable diseases

community immunity

new vaccines

global public health

global u5 mortality

era of global pandemics

newborns immunity